Aura Biosciences Inc. (AURA)
NASDAQ: AURA
· Real-Time Price · USD
6.16
0.09 (1.48%)
At close: May 02, 2025, 3:59 PM
6.15
-0.16%
After-hours: May 02, 2025, 04:05 PM EDT
Company Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer.
The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology.
It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
It also develops AU-011 in additional ocular oncology indications, including choroidal metastases.
The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Aura Biosciences Inc.
| Country | United States |
| IPO Date | Oct 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Dr. Elisabet de los Pinos Ph.D. |
Contact Details
Address: 85 Bolton Street Cambridge, Massachusetts United States | |
| Website | https://www.aurabiosciences.com |
Stock Details
| Ticker Symbol | AURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501796 |
| CUSIP Number | 05153U107 |
| ISIN Number | US05153U1079 |
| Employer ID | 32-0271970 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Elisabet de los Pinos Ph.D. | Founder, Chief Executive Officer, President & Director |
| Dr. Sabine Brookman-May | Senior Vice President & Therapeutic Area Head of Urologic Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Filing |
| Apr 24, 2025 | DEF 14A | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 11, 2025 | SCHEDULE 13G | Filing |
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 3 | Filing |
| Apr 02, 2025 | 8-K | Current Report |
| Mar 24, 2025 | S-8 | Filing |